Irbesartan Production Cost Reports

The report provides detailed analysis essential for establishing an irbesartan production plant. It encompasses all critical aspects necessary for irbesartan production, including the cost of irbesartan production, irbesartan plant cost, irbesartan production costs, and the overall irbesartan production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating an irbesartan production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Irbesartan Market Analysis: Demand and Supply Analysis, and Sourcing

Irbesartan is an angiotensin receptor blocker used to treat high blood pressure. Chemically it is a biphenyl-tetrazole joined to a spiro imidazolinone core with a butyl group. It works by blocking the AT1 receptor for angiotensin II, which relaxes blood vessels and lowers pressure. The drug also treats kidney disease in people with type 2 diabetes and high blood pressure. Being an off-patent generic, it holds broad, steady, and global demand. First approved in the late 1990s as Avapro and Aprovel, it is now a low-cost generic worldwide. By now the molecule is mature, cheap, and made at large scale.

Buyers are pharmaceutical and generic drug makers, along with API traders and distributors. Demand runs through single-agent tablets and fixed-dose combinations with a diuretic. Supply is concentrated in China and India, where large sartan plants run the bulk of world capacity. An irbesartan demand and supply analysis has to weigh cyanobiphenyl intermediate cost, tetrazole and azide chemistry, nitrosamine-impurity control, and steady antihypertensive demand. On receipt, buyers check assay by HPLC, related substances, genotoxic and nitrosamine impurities, residual solvents, and polymorph form.

Summary of the Product, Grades, and Uses

Irbesartan carries the molecular formula C25H28N6O and a molar mass of 428.53 g/mol under CAS 138402-11-6. It is a white to off-white crystalline powder that is practically insoluble in water and soluble in some organic solvents. The melting point runs around 180 to 181 °C, and the compound shows polymorphism, with a higher-melting form B. Being a tetrazole sartan, it needs tight control of azide-related and nitrosamine impurities during synthesis. It is stable as a dry solid, and that stability keeps handling and storage simple. In storage, it holds up well when kept cool, dry, sealed, and away from light.

Irbesartan reaches the market mainly as pharmaceutical grade for oral use. Pharmaceutical grade meets USP, European Pharmacopoeia, and BP monographs, with tight polymorph and impurity control. Indian Pharmacopoeia grade serves the home market under the same tight limits. It ships as a fine crystalline powder to suit tableting and combination products. Buyers check assay by HPLC, related substances, genotoxic and nitrosamine impurities, residual solvents, and microbial limits against the specification.

Across the label, the roles span blood pressure and kidney protection. In hypertension, it lowers blood pressure alone or with a diuretic in a fixed-dose combination. In diabetic kidney disease, it slows the decline of kidney function in type 2 diabetes with high blood pressure. The once-daily dosing and clean tolerability make it a common first-line antihypertensive. Across these uses, the value comes from once-daily dosing, tolerability, low cost, and a long safety record. Demand is broad and steady. The molecule is not going away soon. Such lab work covers impurity standards, method development, stability studies, and analytical checks. Reference and research use is small, mostly analytical and impurity work in labs.

Main End-Uses of Irbesartan

The main use of irbesartan is as an oral antihypertensive, and this covers most demand. In practice, it goes into single-agent tablets and fixed-dose combinations with hydrochlorothiazide. Buyers are pharmaceutical and generic formulators who run cardiovascular lines. On this outlet, they weigh assay, related substances, nitrosamine limits, and reliable supply. Used as a bulk active, one batch serves a large number of finished doses. On the buyer side, checks cover assay, related substances, nitrosamine impurities, and dissolution. For a sartan API, the sensitive attributes are nitrosamine and azido impurities, related substances, polymorph form, and assay.

Hypertension treatment is the largest setting. Doctors use it once daily for high blood pressure, often with a diuretic when a single agent is not enough. A broad, steady prescribing base drives most of the volume. On uptake, the drivers are efficacy, tolerability, once-daily dosing, and low cost. Here the value comes from once-daily dosing, tolerability, low cost, and compendial quality. Sartans are a large class. Price competition is heavy. Formulators value a clean impurity profile here, since the product goes into long-term daily use.

Diabetic kidney protection is the second major setting. In type 2 diabetes with high blood pressure, it slows kidney damage and protects renal function over time. Some markets also use it broadly across cardiovascular risk management. In this role, prescribers weigh blood-pressure control, kidney protection, tolerability, and cost. On the specification side, the key attributes are nitrosamine impurities, related substances, polymorph form, and assay. Reference and comparator use accounts for the small remainder of demand, covering impurity standards, method development, and analytical work in labs.

Irbesartan Market Risks

Irbesartan sits in the generic sartan market, so its main risks are price pressure and impurity control rather than demand. Competition is heavy, since many makers produce the same sartan at low margins. Supply leans on China and India, so any policy shift, energy swing, or plant action there moves the whole market. Nitrosamine and genotoxic impurities are the sharpest quality risk, since the sartan class has faced recalls and tighter limits. Environmental and safety rules on azide chemistry and solvents have also tightened, especially in China. On balance, the main pressures are price competition, supply concentration, impurity control, and tighter rules. Demand itself holds up well. Most risk sits on cost and quality.

Irbesartan manufacturing carries its own risks because the tetrazole chemistry and impurity control both demand tight work. The tetrazole ring is formed with azide reagents, which are hazardous and need careful, contained handling. Nitrosamine and azido impurities have to be kept below strict limits, so process design and testing are demanding. Polymorph form has to be controlled, since the wrong crystal form changes the product. The alkylation and ring-forming steps have to run clean, or related substances build up. Most rejected batches trace back to nitrosamine and azido impurities, related substances, and polymorph or assay failures.

Irbesartan Production Process and Main Cost Drivers

The irbesartan production process runs the full value chain, from spiro imidazolinone and cyanobiphenyl receipt through N-alkylation, tetrazole formation, purification, polymorph control, crystallization, and drying.

1. By N-Alkylation of the Spiro Imidazolinone and Tetrazole Ring Formation: The main inputs are 2-n-butyl-1,3-diazaspiro[4,4]non-1-en-4-one, 4-(bromomethyl)-2'-cyanobiphenyl, an azide reagent, base, organic solvents & purified water.

Irbesartan production opens with receipt and QC of the spiro imidazolinone core and the cyanobiphenyl fragment. The spiro imidazolinone is N-alkylated with 4-(bromomethyl)-2'-cyanobiphenyl under base, which joins the biphenyl to the core. This builds the N-benzyl cyanobiphenyl intermediate, the direct precursor to the drug. The intermediate is purified before the next step, and checks cover assay, related substances, and color, since impurities carry forward otherwise.

Next, the nitrile on the biphenyl is converted to a tetrazole ring with an azide reagent, which completes the irbesartan structure. The crude is worked up, then purified and crystallized under conditions that fix the correct polymorph. The product is filtered, dried & milled to specification under impurity control. Across the process, the critical controls are alkylation selectivity, tetrazole formation, nitrosamine and azido impurities, and polymorph form. Azide handling is contained and controlled, since the reagents are hazardous. QC covers assay, related substances, genotoxic and nitrosamine impurities, residual solvents, and polymorph. The main levers on cost are the cyanobiphenyl intermediate price, tetrazole yield, impurity control, and purification recovery.

Main Factors Affecting Irbesartan Production Cost

Irbesartan production cost is shaped mainly by the cyanobiphenyl intermediate and the spiro imidazolinone core. The cyanobiphenyl fragment is the costliest raw material, since it is a multi-step specialty intermediate. Because the route runs several chemical steps, yield losses compound and shape the cost per kilogram. The azide reagent, base & solvents are steady process costs. Energy for the reactions, purification & drying is a real utility item. On the testing side, HPLC for related substances, nitrosamine and genotoxic tests & polymorph checks make up a large share of the QC spend. On the running side, the biggest cost lines are the intermediates, energy, solvents, and impurity testing. Feedstock is the main driver. Impurity control comes next.

Unit cost also moves with impurity control and polymorph consistency. A batch with high nitrosamine, azido residues, or the wrong crystal form takes extra work and loses yield. Because the sartan class faces strict nitrosamine limits, testing and process control add real cost. Azide handling and safety measures are ongoing process costs, since the reagents are hazardous. GMP documentation, pharmacopoeia compliance & regulatory upkeep are carried as fixed overhead. The synthesis train, purification & impurity-control burden all carry heavy fixed overhead, so a plant running below capacity spreads that overhead over fewer kilograms and lands at a higher unit cost.

Raw Materials for Irbesartan Production Plant and its Procurement

Raw material sourcing for irbesartan centers on the cyanobiphenyl fragment and the spiro imidazolinone core. The cyanobiphenyl intermediate is the primary specialty feedstock, made through its own multi-step synthesis at fine-chemical plants. It ships from a limited set of makers, mostly in China where sartan intermediate capacity is concentrated today. The spiro imidazolinone core, the azide reagent, base, organic solvents, and purified water complete the input streams.

The cheapest cyanobiphenyl is not always the cheapest route to finished irbesartan. A feed with related impurities carries side products through the alkylation. Feedstock quality also shapes the nitrosamine and related-substance profile, which is critical for a sartan. Taken together, cyanobiphenyl purity, alkylation selectivity, tetrazole yield, solvent recovery & purification recovery drive most of the variable cost per kilogram.

These sensitivities shape how an irbesartan plant buys and qualifies its inputs. Contracts specify intermediate purity, related impurities, nitrosamine markers & moisture, and every incoming lot is quarantined until QC release. Vendor qualification runs through supplier audits, review of the synthesis chain & lot-to-lot monitoring. On the incoming side, checks cover assay, related impurities, nitrosamine risk, and moisture. Long-term agreements with two intermediate suppliers help steady cost, timing, quality, and supply. Siting the plant inside a sartan cluster with intermediate supply adds real freight, feedstock & compliance advantages, since the cyanobiphenyl is made nearby.

Sustainability and Regulatory Requirements

Irbesartan manufacture raises environmental concerns that center on azide handling, solvent use & nitrosamine control. Standard controls rely on safe azide handling and destruction, solvent recovery, chemical effluent treatment, and control of genotoxic and nitrosamine traces. Azide reagents are the sharpest handling concern, since they are hazardous, so containment and destruction matter. Solvent recovery and energy integration cut both cost and footprint. On the sustainability side, the themes are azide safety, solvent recovery, effluent treatment, and nitrosamine control. Nitrosamine risk is a specific concern across the sartan class, since these impurities are genotoxic and tightly limited. Nitrosamine control is the sharpest issue. Full documentation is expected.

Regulatory obligations for irbesartan follow from its use as a widely prescribed generic drug. In the US, the API sits under FDA cGMP per 21 CFR 210/211 and the USP monograph. In Europe, an EU GMP site with a Certificate of Suitability to the European Pharmacopoeia is needed for regulated supply. ICH Q7 for active ingredients applies, along with ICH nitrosamine guidance and BP, EP & USP limits. Indian grades follow their own pharmacopoeia limits. On the compliance side, the duties span cGMP, the compendial monograph, nitrosamine and genotoxic limits, and effluent standards. Sites usually carry ISO 14001 and ISO 45001 certification, and batch release rests on assay, related substances, nitrosamine impurities, and polymorph.

CAPEX and OPEX for an Irbesartan Production Plant

An irbesartan plant is a multi-step synthesis and purification facility built around tetrazole chemistry. Plant investment starts with intermediate and reagent storage, an N-alkylation reactor, and an intermediate purification section. From there come a tetrazole-formation reactor with contained azide handling, a purification and polymorph-control step, and a crystallization, drying & milling suite. Utilities cover chilled brine, steam, purified water, solvent recovery, azide containment, and an effluent treatment plant. On the QC side, a laboratory block houses HPLC, nitrosamine and genotoxic-impurity testing, polymorph, residual-solvent, and water analysis. Civil works provide contained reactor bays, a solvent store, a drying and packing area, and a controlled-access warehouse. On the capital side, the big blocks are the synthesis reactors, the azide-handling system, the purification train, and the drying suite. Contained azide handling runs through the tetrazole step, since the reagents are hazardous.

Irbesartan operating cost comes from the same inputs and control points that shape the process. The variable side is led by the cyanobiphenyl intermediate, the spiro imidazolinone, the azide reagent & solvents, alongside energy, labor, testing, effluent treatment, packaging & freight. Cost per kilogram then comes down to tetrazole yield, purification recovery & impurity control. The irbesartan plant setup cost depends on capacity, synthesis and purification scale, azide-handling scope, and grade range. Taken together, intermediate price, tetrazole yield, impurity control, energy use & compliance determine the running cost.

Plant Location and Investment Factors

A workable irbesartan site sits inside a sartan cluster with intermediate supply and strong effluent infrastructure. Access to trained synthesis and QC staff is essential. China's fine-chemical hubs pair cyanobiphenyl supply with tetrazole chemistry and effluent capacity. India adds synthesis and formulation capacity, close to generic drug makers. Both regions offer a low cost base, deep supplier networks & established sartan supply chains. The site also needs azide handling, solvent recovery & a full effluent treatment plant for chemical waste.

For an irbesartan plant, the main investment decision is whether to make the cyanobiphenyl intermediate in-house or buy it and run only the final steps. Buying the intermediate lowers capital but leaves the biggest cost exposed to the intermediate market. Making it in-house raises CAPEX but secures supply and captures more value. Whether to serve regulated markets or price-driven generic markets is the other decision, since regulated grades need tighter nitrosamine and impurity control. Plant scale has to match steady but price-sensitive demand, so the project rests on cost leadership and reliable quality. For a maker targeting regulated markets, nitrosamine control & compendial quality matter most. Regulated grades pay better. Generic grades move volume.

Major Irbesartan Producing Regions

China and India are the core production regions for irbesartan today. China runs most of the world's sartan intermediate and API capacity, backed by large fine-chemical clusters. Regional strength rests on cheap intermediates, scale, integration, and existing effluent capacity. India adds strong API and finished-dose capacity, serving regulated and export markets. Europe holds limited but high-value capacity through specialty API makers for regulated markets. The United States relies mainly on imported API, with finished-dose and specialty work at home. Across the map, the value chain spans the cyanobiphenyl fragment, the spiro imidazolinone, tetrazole formation, and impurity control. A new plant would most likely start in a Chinese or Indian sartan cluster with existing intermediate and effluent capacity.

Key Irbesartan Producers

Zhejiang Huahai Pharmaceutical

• Ranks among the largest Chinese sartan API makers with wide export supply.
• Produces irbesartan and other sartans from an integrated intermediate and synthesis base.
• Competes on a low Chinese cost base, scale & a broad sartan portfolio.
• Regulatory work covers Chinese and export standards, with nitrosamine controls after the sartan review.

Zhejiang Tianyu Pharmaceutical

• Operates as a major Chinese maker of sartans and tetrazole intermediates at large scale.
• Produces irbesartan API and supplies intermediates to other makers.
• Competes on tetrazole capacity, scale & a low cost base.
• Regulatory work covers Chinese and export standards, with tightened impurity controls.

Aurobindo Pharma

• Manufactures a broad API and finished-dose range, including irbesartan, from India.
• Runs multi-step synthesis and formulation for regulated and emerging markets.
• Competes on scale, backward integration & wide regulatory coverage.
• Regulatory record covers US FDA, EU GMP & multi-country approvals.

Dr. Reddy's Laboratories

• Operates as a major Indian API and formulation maker with a broad cardiovascular range.
• Produces irbesartan and other sartans for regulated markets.
• Competes on integration, scale & wide regulatory coverage.
• Regulatory record covers US FDA, EU GMP & multi-country approvals.

Lupin

• Manufactures cardiovascular APIs and finished doses, including irbesartan, from India.
• Supplies captive formulation lines and external customers across markets.
• Competes on scale, generic breadth & wide regulatory coverage.
• Regulatory record covers US FDA, EU GMP & multi-country approvals.

Hetero Drugs

• Runs large API and intermediate capacity from its base in India across many therapy areas.
• Produces sartans, including irbesartan, for regulated and emerging markets.
• Competes on scale, integration & a low cost base.
• Regulatory record covers US FDA, EU GMP & multi-country approvals.